On Apr. 4, 2023, NanoViricides announced that it had executed a license agreement with Karveer Meditech, Kolhapur, India, whereby Karveer received the right to commercialize the Company’s COVID drugs NV-CoV-2 and NV-CoV-2-R in India.

NV-CoV-2 is referred to as a ﾓre-infection blockerﾔ by the company. The drug is designed to directly attack the virus and disable it.